Efficacy and safety of itopride SR for upper gastrointestinal symptoms in patients with diabetic gastroparesis: real-world evidence from Pakistan

Q2 Pharmacology, Toxicology and Pharmaceutics Drugs in Context Pub Date : 2023-12-19 DOI:10.7573/dic.2023-6-4

Adil Ramzan, Ghulam Fareed Memon, Asif Ali, Muhammad Masood, Tariq Meher, Adnan Ghafoor, Naveed Ahmed Shehzad, Safian Ahmed, Zunaira Nawaz, Muhammad Rehan, Tariq Saeed, Waqar Taj, Sakhawat Abbass, Ramiz Khan, Hamza Ehsan, Abubakkar Alam, Bilal Manzoor, Muhammad Nawaz Khan, Khalid Mahmood Yahya, Farhan Mukhtiar, Muhammad Asif Javed, Muhammad Usman Sheikh, Danish Janjua, Sumerah Jabeen, Junaid Zafar, Riaz Hussain Khokar, Madeeha Nazar, N. Maheshwary, Muhammad Athar Khan

{"title":"Efficacy and safety of itopride SR for upper gastrointestinal symptoms in patients with diabetic gastroparesis: real-world evidence from Pakistan","authors":"Adil Ramzan, Ghulam Fareed Memon, Asif Ali, Muhammad Masood, Tariq Meher, Adnan Ghafoor, Naveed Ahmed Shehzad, Safian Ahmed, Zunaira Nawaz, Muhammad Rehan, Tariq Saeed, Waqar Taj, Sakhawat Abbass, Ramiz Khan, Hamza Ehsan, Abubakkar Alam, Bilal Manzoor, Muhammad Nawaz Khan, Khalid Mahmood Yahya, Farhan Mukhtiar, Muhammad Asif Javed, Muhammad Usman Sheikh, Danish Janjua, Sumerah Jabeen, Junaid Zafar, Riaz Hussain Khokar, Madeeha Nazar, N. Maheshwary, Muhammad Athar Khan","doi":"10.7573/dic.2023-6-4","DOIUrl":null,"url":null,"abstract":"Background: Gastroparesis is a serious condition that can be caused by diabetes, surgery or infection, or can be idiopathic. When there is no mechanical obstruction, gastroparesis is characterized by delayed stomach emptying. Itopride, a prokinetic drug, inhibits acetylcholinesterase activity in addition to antagonizing dopamine D2 receptors. Methods: This prospective, multicentre study is based on real-world data from 988 patients with a diagnosis of diabetic gastroparesis for index (PAGI-SYM2) evaluation at baseline and week 4 of treatment for upper gastrointestinal disorder symptoms. Results: Upper gastrointestinal symptom severity scores improved significantly after 4 weeks of treat-ment ( p <0.001), with significant improvement across all categories of gastroparesis (very mild (37–58.6%), mild degree (24.6–31.6%), moderate (29.3–7.3%) and severe (8.8–2.6%).","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":" 916","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs in Context","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7573/dic.2023-6-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Gastroparesis is a serious condition that can be caused by diabetes, surgery or infection, or can be idiopathic. When there is no mechanical obstruction, gastroparesis is characterized by delayed stomach emptying. Itopride, a prokinetic drug, inhibits acetylcholinesterase activity in addition to antagonizing dopamine D2 receptors. Methods: This prospective, multicentre study is based on real-world data from 988 patients with a diagnosis of diabetic gastroparesis for index (PAGI-SYM2) evaluation at baseline and week 4 of treatment for upper gastrointestinal disorder symptoms. Results: Upper gastrointestinal symptom severity scores improved significantly after 4 weeks of treat-ment ( p <0.001), with significant improvement across all categories of gastroparesis (very mild (37–58.6%), mild degree (24.6–31.6%), moderate (29.3–7.3%) and severe (8.8–2.6%).

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

伊托必利 SR 治疗糖尿病胃轻瘫患者上消化道症状的有效性和安全性：来自巴基斯坦的实际证据

背景：胃瘫是一种严重的疾病，可能由糖尿病、手术或感染引起，也可能是特发性的。在没有机械性梗阻的情况下，胃瘫的特点是胃排空延迟。伊托必利是一种促动力药物，除了拮抗多巴胺 D2 受体外，还能抑制乙酰胆碱酯酶的活性。治疗方法这项前瞻性多中心研究基于 988 名诊断为糖尿病胃瘫的患者在治疗上消化道紊乱症状的基线和第 4 周进行指数（PAGI-SYM2）评估的真实数据。结果显示治疗 4 周后，上消化道症状严重程度评分明显改善（P <0.001），所有胃瘫类别（极轻度（37-58.6%）、轻度（24.6-31.6%）、中度（29.3-7.3%）和重度（8.8-2.6%））均有显著改善。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Drugs in Context Medicine-Medicine (all)

CiteScore

5.90

自引率

0.00%

发文量

审稿时长

9 weeks

期刊介绍： Covers all phases of original research: laboratory, animal and human/clinical studies, health economics and outcomes research, and postmarketing studies. Original research that shows positive or negative results are welcomed. Invited review articles may cover single-drug reviews, drug class reviews, latest advances in drug therapy, therapeutic-area reviews, place-in-therapy reviews, new pathways and classes of drugs. In addition, systematic reviews and meta-analyses are welcomed and may be published as original research if performed per accepted guidelines. Editorials of key topics and issues in drugs and therapeutics are welcomed. The Editor-in-Chief will also consider manuscripts of interest in areas such as technologies that support diagnosis, assessment and treatment. EQUATOR Network reporting guidelines should be followed for each article type. GPP3 Guidelines should be followed for any industry-sponsored manuscripts. Other Editorial sections may include Editorial, Case Report, Conference Report, Letter-to-the-Editor, Educational Section.